article Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates 4 June 2020 | By Aslihan Gokaltun (Harvard Medical School and Shriners Hospitals for Children), Beyza Bulutoglu (Harvard Medical School and Shriners Hospitals for Children), Camilo Rey-Bedón (Harvard Medical School and Shriners Hospitals for Children), Martin L Yarmush (Harvard Medical School and Shriners Hospitals for Children), Osman Berk Usta (Harvard Medical School and Shriners Hospitals for Children), Peony Banik (Harvard Medical School and Shriners Hospitals for Children) The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.